321 related articles for article (PubMed ID: 20804212)
1. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
Tao Z; Barker J; Shi SD; Gehring M; Sun S
Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
3. Distribution and association of mTOR with its cofactors, raptor and rictor, in cumulus cells and oocytes during meiotic maturation in mice.
Kogasaka Y; Hoshino Y; Hiradate Y; Tanemura K; Sato E
Mol Reprod Dev; 2013 Apr; 80(4):334-48. PubMed ID: 23440873
[TBL] [Abstract][Full Text] [Related]
4. mTOR phosphorylated at S2448 binds to raptor and rictor.
Rosner M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2010 Jan; 38(1):223-8. PubMed ID: 19145465
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.
Rosner M; Hengstschläger M
Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
[TBL] [Abstract][Full Text] [Related]
9. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor.
Yu K; Toral-Barza L
Methods Mol Biol; 2012; 821():15-28. PubMed ID: 22125057
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation.
Carrière A; Cargnello M; Julien LA; Gao H; Bonneil E; Thibault P; Roux PP
Curr Biol; 2008 Sep; 18(17):1269-77. PubMed ID: 18722121
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
13. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
Lieberthal W; Levine JS
Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
[TBL] [Abstract][Full Text] [Related]
16. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
17. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.
Ekim B; Magnuson B; Acosta-Jaquez HA; Keller JA; Feener EP; Fingar DC
Mol Cell Biol; 2011 Jul; 31(14):2787-801. PubMed ID: 21576368
[TBL] [Abstract][Full Text] [Related]
18. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.
Smrz D; Kim MS; Zhang S; Mock BA; Smrzová S; DuBois W; Simakova O; Maric I; Wilson TM; Metcalfe DD; Gilfillan AM
Blood; 2011 Dec; 118(26):6803-13. PubMed ID: 22053105
[TBL] [Abstract][Full Text] [Related]
20. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
